Florida is taking obesity seriously. Now is time for the next step | Column by Joe Nadglowski, President and CEO of the OAC
March 30, 2026 - Florida’s Weight Management Pilot Program for state employees is an important step in addressing obesity as a chronic disease and improving access to care.
CMS Announces the Medicare GLP-1 Bridge
December 23, 2025 - The Centers for Medicare & Medicaid Services (CMS) announced the Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model and a separate short-term demonstration (“Medicare GLP-1 Bridge”) that will begin in July 2026.
White House Strikes Deals for Lower Prices on Obesity Management Medications
November 6, 2025 - The Trump Administration announced deals with Novo Nordisk, which makes Ozempic and Wegovy, and Eli Lilly, which makes Mounjaro and Zepbound.
FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
February 21, 2025 - FDA has determined the shortage of semaglutide and tirzepatide injection products is resolved.
Biden Administration Proposes CMS Coverage for Anti-Obesity Medication
November 26, 2024 - Biden-Harris Administration Takes Latest Step to Lower Prescription Drug Costs by Proposing Expanded Coverage of Anti-Obesity Medications for Americans with Medicare and Medicaid
TROA Passed in the House Ways and Means Committee
Thursday, June 27, 2024 (ConscienHealth) -- The House Ways & Means Committee advanced on a bipartisan basis the amended Treat and Reduce Obesity Act (TROA) that would allow Medicare to cover anti-obesity medication, but only for those already taking the medications.
Medicare to Cover Wegovy When Patients Also Have Heart Disease
FRIDAY, March 22, 2024 (HealthDay News) -- Medicare will now cover the popular weight-loss drug Wegovy if patients using it also have heart disease, U.S. officials announced Thursday.
